- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 173029, 12 pages
Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
1Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
2University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
3Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
4Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Received 27 January 2012; Accepted 6 March 2012
Academic Editor: Masoud H. Manjili
Copyright © 2012 Vera Levina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
- R. Kim, M. Emi, and K. Tanabe, “Cancer immunoediting from immune surveillance to immune escape,” Immunology, vol. 121, no. 1, pp. 1–14, 2007.
- T. Raskovalova, A. Lokshin, X. Huang et al., “Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling,” Cancer Research, vol. 67, no. 12, pp. 5949–5956, 2007.
- Y. Su, E. K. Jackson, and E. Gorelik, “Receptor desensitization and blockade of the suppressive effects of prostaglandin E2and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes,” Cancer Immunology, Immunotherapy, vol. 60, no. 1, pp. 111–122, 2011.
- A. J. Muller, J. B. DuHadaway, P. S. Donover, E. Sutanto-Ward, and G. C. Prendergast, “Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy,” Nature Medicine, vol. 11, no. 3, pp. 312–319, 2005.
- A. J. Muller, W. P. Malachowski, and G. C. Prendergast, “Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors,” Expert Opinion on Therapeutic Targets, vol. 9, no. 4, pp. 831–849, 2005.
- D. H. Munn, “Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation,” Current Opinion in Immunology, vol. 18, no. 2, pp. 220–225, 2006.
- D. H. Munn and A. L. Mellor, “Indoleamine 2,3-dioxygenase and tumor-induced tolerance,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147–1154, 2007.
- D. H. Munn and A. L. Mellor, “IDO and tolerance to tumors,” Trends in Molecular Medicine, vol. 10, no. 1, pp. 15–18, 2004.
- Y. Kudo and C. A. R. Boyd, “Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection,” Biochimica et Biophysica Acta, vol. 1500, no. 1, pp. 119–124, 2000.
- A. L. Mellor and D. H. Munn, “Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?” Immunology Today, vol. 20, no. 10, pp. 469–473, 1999.
- D. H. Munn, E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor, “Inhibition of T cell proliferation by macrophage tryptophan catabolism,” Journal of Experimental Medicine, vol. 189, no. 9, pp. 1363–1372, 1999.
- G. C. Prendergast, “Immune escape as a fundamental trait of cancer: focus on IDO,” Oncogene, vol. 27, no. 28, pp. 3889–3900, 2008.
- G. C. Prendergast, R. Metz, and A. J. Muller, “IDO recruits Tregs in melanoma,” Cell Cycle, vol. 8, no. 12, pp. 1818–1819, 2009.
- R. Yoshida and O. Hayaishi, “Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 8, pp. 3998–4000, 1978.
- R. Yoshida, J. Imanishi, and T. Oku, “Induction of pulmonary indoleamine 2,3-dioxygenase by interferon,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 1, pp. 129–132, 1981.
- S. Lob, A. Königsrainer, H. G. Rammensee, G. Opelz, and P. Terness, “Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?” Nature Reviews Cancer, vol. 9, no. 6, pp. 445–452, 2009.
- D. H. Munn, M. Zhou, J. T. Attwood et al., “Prevention of allogeneic fetal rejection by tryptophan catabolism,” Science, vol. 281, no. 5380, pp. 1191–1193, 1998.
- L. Huang, B. Baban, B. A. Johnson, and A. L. Mellor, “Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege,” International Reviews of Immunology, vol. 29, no. 2, pp. 133–155, 2010.
- P. Ligam, U. Manuelpillai, E. M. Wallace, and D. Walker, “Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy,” Placenta, vol. 26, no. 6, pp. 498–504, 2005.
- N. Miwa, S. Hayakawa, S. Miyazaki et al., “IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-γ increase in normal pregnancy but decrease in spontaneous abortion,” Molecular Human Reproduction, vol. 11, no. 12, pp. 865–870, 2006.
- C. Uyttenhove, L. Pilotte, I. Théate et al., “Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase,” Nature Medicine, vol. 9, no. 10, pp. 1269–1274, 2003.
- M. Friberg, R. Jennings, M. Alsarraj et al., “Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection,” International Journal of Cancer, vol. 101, no. 2, pp. 151–155, 2002.
- M. D. Sharma, B. Baban, P. Chandler et al., “Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2570–2582, 2007.
- A. J. Muller and G. C. Prendergast, “Indoleamine 2,3-dioxygenase in immune suppression and cancer,” Current Cancer Drug Targets, vol. 7, no. 1, pp. 31–40, 2007.
- A. J. Muller, M. D. Sharma, P. R. Chandler et al., “Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17073–17078, 2008.
- J. Godin-Ethier, L. A. Hanafi, C. A. Piccirillo, and R. Lapointe, “Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives,” Clinical Cancer Research, vol. 17, no. 22, pp. 6985–6991, 2011.
- D. H. Munn, A. L. Mellor, M. Rossi, and J. W. Young, “Dendritic cells have the option to express IDO-mediated suppression or not ,” Blood, vol. 105, no. 6, p. 2618, 2005.
- N. Yoshida, K. Ino, Y. Ishida et al., “Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapidtumor growth in a mouse xenograft model,” Clinical Cancer Research, vol. 14, no. 22, pp. 7251–7259, 2008.
- O. Takikawa, T. Kuroiwa, F. Yamazaki, and R. Kido, “Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon -γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity,” Journal of Biological Chemistry, vol. 263, no. 4, pp. 2041–2048, 1988.
- V. Levina, Y. Su, B. Nolen et al., “Chemotherapeutic drugs and human tumor cells cytokine network,” International Journal of Cancer, vol. 123, no. 9, pp. 2031–2040, 2008.
- C. J. Aslakson and F. R. Miller, “Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor,” Cancer Research, vol. 52, no. 6, pp. 1399–1405, 1992.
- B. A. Pulaski and S. Ostrand-Rosenberg, “Unit 20.2 mouse 4T1 breast tumor model,” in Current Protocols in Immunology, chapter 20, John Wiley & Sons, New York, NY, USA, 2001.
- R. T. Reilly, M. B. C. Gottlieb, A. M. Ercolini et al., “HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice,” Cancer Research, vol. 60, no. 13, pp. 3569–3576, 2000.
- M. B. Kastan and D. S. Lim, “The many substrates and functions of ATM,” Nature Reviews Molecular Cell Biology, vol. 1, no. 3, pp. 179–186, 2000.
- C. Laronga, H. Y. Yang, C. Neal, and M. H. Lee, “Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression,” Journal of Biological Chemistry, vol. 275, no. 30, pp. 23106–23112, 2000.
- X. Zheng, J. Koropatnick, M. Li et al., “Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference,” Journal of Immunology, vol. 177, no. 8, pp. 5639–5646, 2006.
- G. C. Prendergast, R. Metz, and A. J. Muller, “Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway,” American Journal of Pathology, vol. 176, no. 5, pp. 2082–2087, 2010.
- A. J. Muller, J. B. Duhadaway, D. Jaller, P. Curtis, R. Metz, and G. C. Prendergast, “Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate,” Cancer Research, vol. 70, no. 5, pp. 1845–1853, 2010.
- M. Hill, V. Pereira, C. Chauveau et al., “Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase,” FASEB Journal, vol. 19, no. 14, pp. 1957–1968, 2005.